EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enhanced Ocular Retention and Anti-Allergic Efficacy of a Novel HA–Ectoine–CMC Eye Drop for Dry Eye Disease Management

Jon Andrade del Olmo, Alejandro Melero, Ander Pino, Nagore Martínez de Cestafe, Oihane Gartziandia, Miguel Ucelay López de Heredia, Josune Torrecilla, Laura Gómez, Sandra Benito Cid, José María Alonso, Raúl Pérez González

Journal of Pharmaceutical and BioTech Industry · 2025

DOI: 10.3390/jpbi2040016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmaceutical and BioTech Industry, 2025. Verfasst von Jon Andrade del Olmo und 10 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: i+Med S. Coop.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dry eye disease (DED) is a multifactorial ocular surface disorder that significantly affects vision and quality of life. While artificial tears are the standard first-line therapy, their effectiveness is limited by the complex pathophysiology of DED. This study evaluated DayDrop® Triple Action, a novel formulation combining hyaluronic acid (HA), ectoine, and carboxymethylcellulose (CMC), designed to enhance tear film stability and ocular surface protection. Physicochemical and rheological properties were assessed, including viscosity, pseudoplasticity, and viscoelastic behaviour under dynamic conditions, along with ectoine release over 24 h. An in vitro allergic conjunctivitis model using conjunctival fibroblasts exposed to a pro-allergic cytokine cocktail was employed to examine immunomodulatory effects. DayDrop® Triple Action demonstrated high viscosity with pronounced pseudoplasticity and stable viscoelasticity, supporting improved mucoadhesion. The formulation provided sustained ectoine release and exhibited a positive immunomodulatory effect, likely linked to ectoine’s preferential hydration mechanism, which stabilizes membranes and reduces inflammatory signalling. These findings suggest that DayDrop® Triple Action integrates viscoelastic optimization, osmoprotection, and targeted anti-inflammatory action, offering a promising non-pharmacological strategy for managing DED and allergic ocular surface disorders.

Förderung

  • i+Med S. Coop

Zitieren

APA

Olmo, J. A. D., Melero, A., Pino, A., Cestafe, N. M. D., Gartziandia, O., Heredia, M. U. L. D., Torrecilla, J., Gómez, L., Cid, S. B., Alonso, J. M., & González, R. P. (2025). Enhanced Ocular Retention and Anti-Allergic Efficacy of a Novel HA–Ectoine–CMC Eye Drop for Dry Eye Disease Management. Journal of Pharmaceutical and BioTech Industry. https://doi.org/10.3390/jpbi2040016

Vancouver

Olmo JAD, Melero A, Pino A, Cestafe NMD, Gartziandia O, Heredia MULD, et al. Enhanced Ocular Retention and Anti-Allergic Efficacy of a Novel HA–Ectoine–CMC Eye Drop for Dry Eye Disease Management. Journal of Pharmaceutical and BioTech Industry. 2025. doi:10.3390/jpbi2040016

BibTeX
@article{Olmo2025,
  author = {Olmo, Jon Andrade del and Melero, Alejandro and Pino, Ander and Cestafe, Nagore Martínez de and Gartziandia, Oihane and Heredia, Miguel Ucelay López de and Torrecilla, Josune and Gómez, Laura and Cid, Sandra Benito and Alonso, José María and González, Raúl Pérez},
  title = {Enhanced Ocular Retention and Anti-Allergic Efficacy of a Novel HA–Ectoine–CMC Eye Drop for Dry Eye Disease Management},
  journal = {Journal of Pharmaceutical and BioTech Industry},
  year = {2025},
  doi = {10.3390/jpbi2040016}
}
Kostenlos starten →